EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis

Yixiao Liu, Kehan Jin, Yingyun Yang, Aiming Yang

European Journal of Internal Medicine · 2024-09 · 127 · 63-73

DOI: 10.1016/j.ejim.2024.06.006 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Internal Medicine, 2024-09. Verfasst von Yixiao Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of M…. Hauptthemen laut MEDLINE: Immunoglobulin G4-Related Disease, Immunologic Factors, Rituximab. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Clinical Key Specialty Project Foundation, Capital Health Research and Development of Special Fund, Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Previous studies have reported that rituximab (RTX) therapy might be beneficial in reducing relapse rates in patients with IgG4-related disease (IgG4-RD). Therefore, we aimed to systematically assess the efficacy and safety of RTX induction treatment and the effect of RTX maintenance in patients with IgG4-RD. METHODS: The protocol was registered in the PROSPERO (CRD42023427352). PubMed, Embase, the Cochrane database, Scopus, and the Web of Science were interrogated to identify studies that evaluated the impact of RTX on prognosis in IgG4-RD. We explored the impact of various subgroups of factors on relapse outcomes and focused on the possible role of maintenance therapy in reducing relapse rates. The pooled incidence of adverse events of RTX therapy and the influencing factors have also been evaluated. RESULTS: Eighteen studies comprising 374 patients (mean age 56.0 ± 8.7 years; male 73.7 %) with a mean follow-up duration of 23.4 ± 16.3 months were included. The pooled estimate of the response rate, complete remission rate, overall relapse rate, adverse event rate, and serious adverse event rate of RTX induction therapy were 97.3 % (95 % CI, 94.7 %-99.1 %), 55.8 % (95 % CI, 39.6 %-71.3 %), 16.9 % (95 % CI, 8.7 %-27.1 %), 31.6 % (95 % CI, 16.7 %-48.9 %) and 3.9 % (95 % CI, 0.8 %-8.9 %), respectively. In subgroup analysis, the pooled relapse rate was significantly lower in studies with maintenance than without maintenance (2.8% vs 21.5 %, p < 0.01). Pooled Kaplan-Meier relapse curves also demonstrated that RTX maintenance therapy provided a better prognosis. CONCLUSIONS: RTX induction therapy appears to have satisfactory efficacy in the induction of remission in IgG4-RD. In addition, prophylactic RTX maintenance therapy after induction may be beneficial in preventing relapse of IgG4-RD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin G4-Related DiseaseImmunologic FactorsRituximabHumansInduction ChemotherapyMaintenance ChemotherapyRecurrenceRemission InductionTreatment Outcome

Stichwörter der Autor:innen

IgG4-related diseaseInduction therapyMaintenance therapyRituximab

Substanzen

Immunologic FactorsRituximab

Autor:innen und Institutionen

  • Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. Electronic address: yangyingyun@pumch…

Förderung

  • National Clinical Key Specialty Project Foundation
  • Capital Health Research and Development of Special Fund
  • Chinese Academy of Medical Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Liu, Y., Jin, K., Yang, Y., & Yang, A. (2024). Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis. European Journal of Internal Medicine, 127, 63-73. https://doi.org/10.1016/j.ejim.2024.06.006

Vancouver

Liu Y, Jin K, Yang Y, Yang A. Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis. European Journal of Internal Medicine. 2024;127:63-73. doi:10.1016/j.ejim.2024.06.006

BibTeX
@article{Liu2024,
  author = {Liu, Yixiao and Jin, Kehan and Yang, Yingyun and Yang, Aiming},
  title = {Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  volume = {127},
  pages = {63--73},
  doi = {10.1016/j.ejim.2024.06.006}
}
Kostenlos starten →